Story

UK Competition Watchdog Launches Review of Akzo Nobel's Axalta Takeover

ENTHMSVIIDZHZH-TWJAKOHI
Sep 17, 20261 min read
UK Competition Watchdog Launches Review of Akzo Nobel's Axalta Takeover

Summary

The UK's Competition and Markets Authority (CMA) has initiated a phase 1 review of the proposed all-stock merger between coatings giants Akzo Nobel and Axalta. The regulator will decide by November 11 whether the deal requires a more in-depth investigation.

Text size
Background

The United Kingdom's competition regulator has officially begun its review of the proposed merger between Dutch paint and coatings company Akzo Nobel and its U.S.-based rival, Axalta Coating Systems. The move marks a critical step in the regulatory approval process for a deal that would combine two major players in the global coatings industry.

Regulatory Scrutiny Begins

The Competition and Markets Authority (CMA) announced on Wednesday that it had accepted the merger notice, formally starting its initial "phase 1" investigation. The review period began on September 17.

The regulator has set a deadline of November 11 to decide whether the transaction could substantially lessen competition within any UK market. Following its initial assessment, the CMA will either clear the merger to proceed or refer it for a more extensive "phase 2" investigation.

Deal Status and Timeline

Sample IUX Markets – In-articleAd

The proposed transaction is an all-stock merger that has already received the green light from shareholders of both companies, who voted in favor of the deal on August 5. According to the companies, the final voting results are to be filed with the U.S. Securities and Exchange Commission.

Despite shareholder approval, the merger's completion remains subject to other regulatory clearances and customary closing conditions. The companies currently expect the transaction to be finalized in late 2026 or early 2027, pending the outcome of reviews like the one initiated by the CMA.

What This Means for Investors

The CMA's review is a standard but crucial hurdle for large-scale mergers. A potential referral to a phase 2 investigation could introduce significant delays and uncertainty for the deal, creating a potential headwind for the shares of both Akzo Nobel and Axalta. Investors will be closely monitoring the CMA's decision in November as a key indicator of the regulatory landscape for the acquisition.

Read next

More on Stocks
Back to latest news

LATEST